Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02030639
Recruitment Status : Completed
First Posted : January 8, 2014
Last Update Posted : June 23, 2017
Sponsor:
Information provided by (Responsible Party):
Onconova Therapeutics, Inc.

Brief Summary:

The purpose of this study is to gain an understanding of how the experimental anti-cancer drug, rigosertib, is metabolized in the body and excreted in the urine and feces after it is given as an intravenous infusion. In addition, the study will be carefully monitored to see if any side effects occur.

A radioactive drug is used in this study because it is easier and more accurate to measure radioactivity than to use more complicated and less sensitive chemical tests for the drug.


Condition or disease Intervention/treatment Phase
Healthy Drug: rigosertib Phase 1

Detailed Description:

This study will be an open-label, non-randomized, metabolism and excretion study of [14C]-rigosertib administered as a single dose of approximately 450 mg containing 250 μCi [14C]-labeled rigosertib as a 24-hour continuous intravenous (CIV) infusion in healthy volunteers. Up to 8 subjects will be enrolled to ensure at least 6 subjects have evaluable data.

Eligible subjects will be confined at the clinical site from the time of Check-in (approximately 24 hours prior to dosing) until Discharge (between Days 6 and 10). One single dose of [14C]-rigosertib will be administered as a 24-hour continuous intravenous infusion on Day 1. Subjects will be discharged as early as 120 hours after the start of the infusion, after ≥ 90% of the administered radioactive dose has been recovered in urine and feces or when the combined total radioactivity recovered in urine and feces is ≤ 1% of the administered radioactive dose for 2 consecutive 24-hr samples. The maximum stay will be until Day 10 (216 hours after the start of the infusion).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Phase I Study of the Metabolism and Excretion of [14C]-Rigosertib After Single-dose Administration as 24-hour Continuous Intravenous Infusion to Healthy Volunteers
Study Start Date : January 2014
Actual Primary Completion Date : December 2014
Actual Study Completion Date : August 2015

Arm Intervention/treatment
Experimental: [14C]-rigosertib
A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
Drug: rigosertib
A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
Other Names:
  • rigosertib sodium
  • ON 01910.Na




Primary Outcome Measures :
  1. The mean percent of the radioactivity of the administered doses recovered in the urine, feces, and overall (urine + feces) [ Time Frame: Up to 216 hours ]
    Urine sample collection for radio analysis will be over the intervals of 24-30 hours (hr), 30-36 hr, 36-42 hr, 42-48 hr, 48-72 hr, 72-96 hr, 96-120 hr, and if necessary based on discharge criteria, at 120-144 hr, 144-168 hr, 168-192 hr, and 192-216 hr after the infusion start. Fecal sample collection for radio analysis will be over the intervals of 24-30 hr, 30-36 hr, 36-42 hr, 42-48 hr, 48-72 hr, 72-96 hr, 96-120 hr, and if necessary based on discharge criteria, at 120-144 hr, 144-168 hr, 168-192 hr, and 192-216 hr after the infusion start.

  2. Concentration of rigosertib in plasma [ Time Frame: Up to 216 hours ]
    Concentration of rigosertib in plasma will be measured by a validated high performance liquid chromatography (HPLC) method. Plasma samples will be collected at 24 hours (hr) (immediately before the end of the infusion), 24.25 hr, 24.5 hr, 25 hr, 26 hr, 28 hr, 30 hr, 36 hr, 48 hr, 72 hr, and 96 hr after the infusion start, and, if the subject has not been discharged by then, at 144 hr, 192 hr, and 216 hr after the infusion start. Concentration values will be used to derive the following pharmacokinetic parameters: Cmax; tmax; AUC0-t; AUC0-∞; λZ; t1/2; CL; Vz; Vss.

  3. Concentration of radioactivity in whole blood [ Time Frame: Up to 216 hours ]
    Blood samples for radio analysis will be collected at 24 hours (hr) (immediately before the end of the infusion), 24.25 hr, 24.5 hr, 25 hr, 26 hr, 28 hr, 30 hr, 36 hr, 48 hr, 72 hr, and 96 hr after the infusion start, and, if the subject has not been discharged by then, at 144 hr, 192 hr, and 216 hr after the infusion start.

  4. Concentration of radioactivity in plasma [ Time Frame: Up to 216 hour ]
    Plasma samples for radio analysis will be collected at 24 hours (hr) (immediately before the end of the infusion), 24.25 hr, 24.5 hr, 25 hr, 26 hr, 28 hr, 30 hr, 36 hr, 48 hr, 72 hr, and 96 hr after the infusion start, and, if the subject has not been discharged by then, at 144 hr, 192 hr, and 216 hr after the infusion start.


Secondary Outcome Measures :
  1. Metabolite profiling [ Time Frame: Up to 216 hours ]
    Extracts from samples of plasma, urine and feces will be subjected to high performance liquid chromatography (HPLC) with radiochemical detection for the quantitative analysis of rigosertib and its metabolites.

  2. Metabolite identification [ Time Frame: Up to 216 hours ]
    Metabolite identification will be carried out by mass spectrometry. Synthetic standards of known metabolites will be used to confirm identifications.

  3. Concentration of radioactivity in urine [ Time Frame: Up to 216 hours ]
    Urine sample collection for radio analysis will be over the intervals of 24-30 hr, 30-36 hr, 36-42 hr, 42-48 hr, 48-72 hr, 72-96 hr, 96-120 hr, and if necessary based on discharge criteria, at 120-144 hr, 144-168 hr, 168-192 hr, and 192-216 hr after the infusion start.

  4. Concentration of radioactivity in feces [ Time Frame: Up to 216 hours ]
    Fecal sample collection for radio analysis will be over the intervals of 24-30 hr, 30-36 hr, 36-42 hr, 42-48 hr, 48-72 hr, 72-96 hr, 96-120 hr, and if necessary based on discharge criteria, at 120-144 hr, 144-168 hr, 168-192 hr, and 192-216 hr after the infusion start.

  5. Number of subjects who experience an adverse event [ Time Frame: Up to 31 days ]
    An adverse event is defined according to ICH E2A guidance.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2, inclusive;
  • In good health, as defined by the absence of clinically significant findings from medical history, 12-lead electrocardiogram (ECG), and vital signs;
  • Clinical laboratory evaluations that are within the normal range, unless deemed not clinically significant by the Investigator. Platelet (PLT) count, white blood cell (WBC) count, and absolute neutrophil count (ANC) should all be above the lower limit of normal (LLN);
  • Negative test for selected drugs of abuse at Screening (does not include alcohol) and at Check-in (does include alcohol);
  • Negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis C virus antibody [anti-HCV]) and negative human immunodeficiency virus (HIV) antibody screens;
  • Males will either be vasectomized or sterile;
  • Female subjects must have undergone confirmed tubal ligation or hysterectomy or be post-menopausal;
  • Able to comprehend and willing to sign an informed consent form (ICF);
  • History of a minimum of 1 bowel movement per day.

Exclusion Criteria:

  • Participation in any other investigational study drug trial in which receipt of an investigational agent, biologic agent, small targeted molecule, or immunotherapy occurred within 5 half-lives or 4 weeks of enrollment, whichever is longer;
  • Major surgery within 3 weeks of enrollment or major surgery without full recovery;
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy and hernia repair will be allowed;
  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder;
  • History of Gilbert's Syndrome;
  • History or presence of an abnormal ECG, which, in the Investigator's opinion, is clinically significant;
  • Uncontrolled hypertension, defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, unless deemed acceptable by the Investigator;
  • History of seizures, except febrile seizures as a child;
  • Psychiatric illness/social situations that would limit the subject's ability to tolerate and/or comply with study requirements, or inability to comply with study and/or follow-up procedures;
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator;
  • History of alcoholism or drug addiction within 1 year prior to Check-in;
  • Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in. The previous radiolabeled study drug must have been received more than 6 months prior to Check-in for this study and the total exposure from this study and the previous study will be within the recommended levels considered safe;
  • Exposure to significant radiation within 12 months prior to Check-in;
  • Use of any prescription medications/products within 14 days prior to Check-in, unless deemed acceptable by the Investigator;
  • Use of any over-the-counter, non-prescription preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator;
  • Poor peripheral venous access;
  • Donation of blood from 30 days prior to Screening through discharge, inclusive, or of plasma from 2 weeks prior to Screening through discharge, inclusive;
  • Receipt of blood products within 2 months prior to Check-in;
  • Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02030639


Locations
Layout table for location information
United States, Wisconsin
Covance Clinical Research Unit, Inc.
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Onconova Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Chair: Francois Wilhelm, MD, PhD Onconova Therapeutics, Inc.

Publications of Results:
Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.

Layout table for additonal information
Responsible Party: Onconova Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02030639     History of Changes
Other Study ID Numbers: Onconova 04-23
8287875 ( Other Identifier: Covance Clinical Research Unit, Inc. )
First Posted: January 8, 2014    Key Record Dates
Last Update Posted: June 23, 2017
Last Verified: June 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
ON 01910
Glycine
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Glycine Agents
Neurotransmitter Agents
Physiological Effects of Drugs